Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1

Antiviral Chemistry and Chemotherapy

Volumn 10, Issue 2, 1999, Pages 79-86

  Taylor, D L ^a   Ahmed, P S ^a   Chambers, P ^a   Tyms, A S ^a   Bedard, J ^b   Duchaine, J ^b   Falardeau, G ^b   Lavallee J F ^b   Brown, W ^b   Rando, R F ^b   Bowlin, T ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b Shire Canada   (Canada)

Author keywords

Anti HIV 1 activity; Drug resistance; Non nucleoside reverse transcriptase inhibitor (NNRTI); Pyrido 1,2a indole derivatives

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; INDOLE DERIVATIVE; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS ENZYME; ZIDOVUDINE;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG RESISTANCE; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS CULTURE; VIRUS REPLICATION;

EID: 0032901392     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029901000204     Document Type: Article

References (37)

1. Baba M, Shigeta S, Yuasa, S, Ubasawa M, Takashima H, Sekiya K, Tanaka H, Miyasaka T, Walker R T & De Clercq E (1994) Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrobial Agents and Chemotherapy 38:688-692.
2. Balzarini J, Perez-Perez M-J, San-Felix A, Schols D, Perno C-F, Vandamme A-M, Camarasa M-J & De Clercq E (1992) 2′,5′-Bis-0-(tert-butyldimethylsilyl)-3′-spiro-5′- (4′-amino-1′,2′-oxathiole-2′,2′ dioxide) pyrimidme (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proceedings of the National Academy of Sciences, USA 89:4392-4396.
3. Balzarini J, Karlsson A, Perez-Perez M-J, Vrang L, Walbers J, Zhang H, Oberg B, Vandamme A-M, Camarasa M-J & De Clercq E (1993) HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology 192:246-253.
4. Balzarini J, Pelemans H, Perez-Perez M-J, Sanfelix A, Camarasa M J, De Clercq E & Karlsson A (1996a) Marked inhibitory activity of nonnucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2′,3′-thiacytidine. Molecular Pharmacology 49:882-890.
5. Balzarini J, Pelemans H, Karlsson A, De Clercq E & Kleim JP (1996b) Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors. Proceedings of the National Academy of Sciences, USA 93:13152-13157.
6. Brennan TM, Taylor DL, Bridges CG, Leyda J & Tyms AS (1994) The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antiviral Research 26:173-187.
7. Buckheit RW, Kinjerski TL, Fliakas-Boltz V, Russell JD, Stup TL, Pallansch LA, Brouwer W G, Dao DC, Harrison WA, Schultz RJ, Bader JP & Yang SS (1996) Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1 specific compounds related to oxathiin carboxanilide. Antimicrobial Agents and Chemotherapy 39:2718-2727.
8. Carr A, Vella S, De Jong MD, Sorice F, Imrie A, Boucher CA & Cooper DA (1996) A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group. AIDS 10:635-641.
9. Chong KT & Pagano PJ (1997) Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine. Antiviral Research 34:51-63.
10. Cohen KA, Hopkins J, Ingraham RH, Pargellis C, Wu JC, Palladino DEH, Kinkade P, Warren TC, Rogers S, Adams J, Farina PR & Grob PM (1991). Characterisation of the binding site for nevirapine (BI-RG-587), a non-nucleoside inhibitor of human immunodeficiency virus type 1 reverse transcriptase. Journal of Biological Chemistry 266:14670-14674.
11. Das K, Ding J, Hsiou Y, Clark AD, Moereels H, Koymans L, Andries K, Pauwels R, Janssen PA, Boyer PL, Clark P, Smith RH, Kroeger-Smith MB, Michejd CJ, Hughes SH & Arnold E (1996) Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Ty181Cys HIV-1 RT drug resistant mutant. Journal of Molecular Biology 264:1085-1100.
12. Davey RT, Chaitt DG, Reed GF, Freimuth WW, Herpin BR, Metcalf JA, Eastman PS, Falloon J, Kovacs JA, Polis MA, Walker RE, Masur H, Boyle J, Coleman S, Cox SR, Wathen L, Daenzer CL & Lane HC (1996) Randomised, controlled Phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type-1 infected patients. Antimicrobial Agents and Chemotherapy 40:1657-1664.
13. Demeter LM, Meehan PM, Morse G, Gerondelis P, Dexter A, Berrios L, Cox S, Freimuth W & Reichman RC (1997) HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 14:136-144.
14. D'Aquila R, Hughes M, Johnson VA, Fischl MA, Sommadossi JP, Liou S-H, Timpone J, Myers M, Basgoz N, Niu M, Hirsch MS and the NIAID AIDS Clinical Trials Group Protocol 241 Investigators (1996) Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection - a randomised, double blind placebo-controlled trial. Annals of Internal Medicine 124:1019-1030.
15. Dueweke TJ, Kezdy FJ, Waszak GA, Deibel MR & Tarpley WG (1992) The binding of a novel bis (heteroaryl) piperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. Journal of Biological Chemistry 267:27-30.
16. Dueweke TJ, Poppe SM, Romero DL, Swaney SM, So AG, Downey KM, Althaus IW, Reusser F, Busso M & Resnick L (1993) U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrobial Agents and Chemotherapy 37:1127-1131.
17. Esnouf R, Ren J, Ross C, Jones Y, Stammers D & Stuart D (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nature Structural Biology 2:303-308.
18. Goldman ME, Nunberg JH, O'Brien JA, Quintero JC, Schleif WA, Freund KF, Gaul SL, Saari WS, Wai JS, Hoffman JM, Anderson PS, Hupe DJ, Emini EA & Stern AM (1991) Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proceedings of the National Academy of Sciences, USA 88:6863-6867.
19. Hart GJ, Orr DC, Penn CR, Figueiredo HT, Gray NM, Boehme RE & Cameron JM (1992) Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrobial Agents and Chemotherapy 36:1688-1694.
20. Hsiou Y, Ding J, Das K, Clark AD, Hughes SH & Arnold E (1996) Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerisation and inhibition mechanisms. Structure 4:853-860.
21. Kleim JP, Bender R, Kirsch R, Meichsner C, Paessens A, Rosner M, Rubsamen-Waigmann H, Kaiser R, Wichers M, Schneweis KE, Winkler I & Riess G (1995) Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrobial Agents and Chemotherapy 39:2253-2257.
22. Koup RA, Brewster F, Grob P & Sullivan JL (1993) Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, Interferon or CD4 immunoadhesin. AIDS 7:1181-1184.
23. Mager PP & Walther H (1996) A hydrophilic omega-loop (Tyr181 to Tyr188) in the nonsubstrate binding area of HIV-1 reverse transcriptase. Drug Design and Discovery 14:225-239.
24. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih C-K, Eckner K, Hattox S, Adams J, Rosenthal AS, Faanes R, Eckner RJ, Koup RA & Sullivan JL. (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250:1411-1413.
25. Nunberg JH, Schleif WA, Boots EJ, O'Brien JA, Quintero JC, Hoffman JM, Emini EA & Goldman ME (1991) Viral resistance to human immunodeficiency virus type-1 specific pyridinone reverse transcriptase inhibitors. Journal of Virology 65:4887-4892.
26. Pagano PJ & Chong KT (1997) Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two- and three-drug combinations of delavirdine, lamivudine and zidovudine. Antiviral Chemistry and Chemotherapy 8:333-341.
27. Pauwels R, Balzarinii J, Schols D, Baba M, Desmyter J, Rosenberg I, Holy A & De Clercq E (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virological Methods 20:309-321.
28. Pauwels R, Andries K, Desmyter J, Schols D, Kukla M, Breslin H, Raeymaekers A, Van Gelder J, Woestenborghs R, Heykants J, Schellekens K, Janssen MAC, De Clercq E & Janssen P (1990) Potent and selective inhibition of HIV-1 replication in vitro by a series of TIBO derivatives. Nature 343:470-474.
29. Piras G, Nakade K, Yuasa S & Baba M (1997) Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1. AIDS 11:469-475.
30. Reichman RC, Morse GD, Demeter LM, Resnick L, Bassiakos Y, Fischl M, Para M, Powderly W, Leedom J, Greisberger C, Nevin T, Wood K, Meehan P, Geheb H, Cox S, Batts D, Timpone J & the ACTG 199 Study Team (1995) Phase 1 study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. Journal of Infectious Diseases 171:297-304.
31. Richman D, Shih CK, Lowy I, Rose J, Prodanovich P, Goff S & Griffin J (1991) Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proceedings of the National Academy of Sciences, USA 88:11241-11245.
32. Romero DL, Busso M, Tan CK, Reusser F, Palmer JR, Poppe SM, Aristoff PA, Downey KM, So AG, Resnick L & Tarpley WG (1991) Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proceedings of the National Academy of Sciences, USA 88:8806-8810.
33. Schinazi R, Larder B & Mellors J (1997) Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. International Antiviral News 5:129-142.
34. Schmit JC, Cogniaux J, Hermans P, Van Vaeck C, Sprecher S, Van Remoortel B, Witrouw M, Balzarini J, Desmyter J, De Clercq E and Vandamme AM (1996) Multiple drug resistance to nucleoside analogues and non nucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. Journal of Infectious Diseases 174:962-968.
35. Staszewski S, Miller V, Rehmet S, Stark T, De Cree J, De Brabander M, Peeters M, Andries K, Moeremans M, De Raeymaeker M, Pearce G, Van den Broeck R, Verbiest W & Stoffels P (1996) Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS 10:F1-7.
36. Taylor DL, Ahmed SP, Brennan TM, Nave J-F, Casara P and Tyms AS (1996) Anti-HIV activity of MDL 74968, a novel acyclonucleotide derivative of guanine: drug resistance and drug combination effects in vitro. Antiviral Chemistry and Chemotherapy 7:253-260.
37. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, Huff JR, Anderson PS, Olsen DB, Carroll SS (1995) L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 39:2602-2605.